GSK Plc is to pay up to $750 million to acquire a new asset for multiple myeloma – its latest move to expand its portfolio for blood cancers. The asset is a trispecific T cell engager, an engineered antibody linking the body’s immune cells directly to antigens on cancer cells. There are currently no approved trispecific T cell engagers, but authorisations have been granted to bispecific T cell engagers, a simpler version of the same therapy.
Announced on 15 September, the deal includes an undisclosed upfront fee and milestone payments.
The multiple myeloma asset originates from Chimagen Biosciences Ltd of China and is expected to enter Phase 1 studies in 2027. It is the second deal between the two companies involving a T cell engager. The first took place in 2024 when GSK acquired CMG1A46 from the Chinese company for the potential treatment of autoimmune diseases including lupus. CMG1A46 has also been studied in blood cancers. The newest asset and CMG1A46 both target tumour-associated antigens whilst recruiting T cells to attack the diseases.
“The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease,” said Hesham Abdullah, global head of oncology at GSK, in a prepared statement.
GSK has a marketed product for multiple myeloma, Blenrep, which is an antibody-drug conjugate that received an accelerated approval from the US Food and Drug Administration in 2020. The license was later revoked after a confirmatory trial didn’t meet its primary endpoint. However in 2025 it was reinstated as a combination therapy with a protease inhibitor and a corticosteroid.
GSK said the newest acquisition could result in a therapy with a broader application and earlier use in multiple myeloma.
Copyright 2026 Evernow Publishing Ltd